MacroGenics Inc. Common Stock (MGNX)
Stock · NASDAQ · Health Care
$3.25as of 10/16/2026
Price chart
Active signals
MGNX Signal Track Record
How signals performed across all stocks →What MGNX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | +2.0% | 57% | September 18, 2026 |
| Bollinger Band Breakout | 27 | -4.8% | 44% | September 2, 2026 |
| Bollinger Band Breakdown | 13 | 0.0% | 46% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -8.5% | 25% | December 22, 2025 |
| Any 20-session window (baseline) | +0.8% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MGNX
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for t…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 293
- Website
- www.macrogenics.com/
Fundamentals
- 1-day range
- $3.3$3.44
- Market cap
- $254.89M
- P/E (trailing)
- —
- P/E (forward)
- -2.30
- EPS (trailing)
- $-0.23
- Dividend yield
- —
- Beta
- 1.25
- Avg. volume
- 593.6K
How MacroGenics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 9, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
MacroGenics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MGNXMacroGenics Inc. Common Stock$3.25▼ 3.56%Market cap $254.89MP/E —$1.29$5.08
- AKBAAkebia Therapeutics Inc. Common Stock$0.67▼ 3.74%Market cap $256.03MP/E —$0.7$3.2
- WHWKWhitehawk Therapeutics Inc. Common Stock$2.89▼ 4.93%Market cap $252.78MP/E —$1.97$5.5
- RNACCartesian Therapeutics Inc. Common Stock$6.27▼ 4.71%Market cap $257.38MP/E —$5.6$11
- VRXAVeraxa Biotech AG Ordinary Shares$1.11▲ 0.91%Market cap $263.02MP/E —$1.04$27.36
- SLGLSol-Gel Technologies Ltd. Ordinary Shares$64.25▼ 6.48%Market cap $244.18MP/E —$28.81$97.97
- TRDAEntrada Therapeutics Inc. Common Stock$4.37▼ 8.58%Market cap $266.70MP/E —$4.11$16.45
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MGNX MacroGenics Inc. Common Stock | $254.89M | — | $3.25 | ▼ 3.56% | $1.29$5.08 |
| AKBA Akebia Therapeutics Inc. Common Stock | $256.03M | — | $0.67 | ▼ 3.74% | $0.7$3.2 |
| WHWK Whitehawk Therapeutics Inc. Common Stock | $252.78M | — | $2.89 | ▼ 4.93% | $1.97$5.5 |
| RNAC Cartesian Therapeutics Inc. Common Stock | $257.38M | — | $6.27 | ▼ 4.71% | $5.6$11 |
| VRXA Veraxa Biotech AG Ordinary Shares | $263.02M | — | $1.11 | ▲ 0.91% | $1.04$27.36 |
| SLGL Sol-Gel Technologies Ltd. Ordinary Shares | $244.18M | — | $64.25 | ▼ 6.48% | $28.81$97.97 |
| TRDA Entrada Therapeutics Inc. Common Stock | $266.70M | — | $4.37 | ▼ 8.58% | $4.11$16.45 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- MacroGenics Doses First Patient In Phase 1 Study Of MGC030, Antibody-Drug Conjugate Directed Against Undisclosed Target, In Patients With Advanced Solid Tumorsbenzinga · 10/15/2026
- Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?Yahoo · 10/9/2026
- Stock Picks From Seeking Alpha's September 2026 New AnalystsSeekingAlpha · 10/7/2026
- Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?Yahoo · 9/23/2026
- MacroGenics (NASDAQ:MGNX): A Minervini Trend Template High-Growth Momentum Case StudyChartMill · 9/18/2026
Insider Activity
Insider Actions →- Bonvini Ezio · October 6, 2026 · Option Exercise8.0K @ $2.6
- Peters Jeffrey Stuart · August 19, 2026 · Sale31.1K @ $4.15
- Bonvini Ezio · August 17, 2026 · Option Exercise40.0K @ $2.6
- Ferrante Karen Jean · May 19, 2026 · Grant22.0K
- Ferrante Karen Jean · May 19, 2026 · Grant3.8K
- Koenig Scott · May 19, 2026 · Grant22.0K
- Koenig Scott · May 19, 2026 · Grant3.8K
- Jackson Scott Thomas · May 19, 2026 · Grant22.0K
- Jackson Scott Thomas · May 19, 2026 · Grant3.8K
- Chhabra Meenu · May 19, 2026 · Grant3.8K
- Chhabra Meenu · May 19, 2026 · Grant22.0K
- Liu Margaret · May 19, 2026 · Grant22.0K
- Liu Margaret · May 19, 2026 · Grant3.8K
- William K. Heiden · May 19, 2026 · Grant22.0K
- William K. Heiden · May 19, 2026 · Grant3.8K
Institutional Ownership
March 31, 2026
- Total shares held
- 41.77M
- Total value held
- $112.11M
- Institutional holders
- 104
- Unknown6.01M
- Unknown2.96M
- Unknown2.79M
- Unknown2.65M
- Unknown2.54M
- Unknown2.53M
- Unknown2.40M
- Unknown2.03M
- Unknown1.86M
- Unknown1.56M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
MGNX mentioned in medical stock sector review
MacroGenics was included in a recent Yahoo Finance article examining the performance of medical stocks this year. The stock is currently trading near its 52-week low, with technical indicators showing weakness near key support levels. This context highlights the broader sector trends affecting the company's valuation.
MGNX mentioned in medical stock sector review. MacroGenics was included in a recent Yahoo Finance article examining the performance of medical stocks this year. The stock is currently trading near its 52-week low, with technical indicators showing weakness near key support levels. This context highlights the broader sector trends affecting the company's valuation.